Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 04 Sep 2021
GSK’s shingles vaccine Shingrix gains UK license
2 September 2021 - GlaxoSmithKline's Shingrix has been licensed in the UK for the prevention of shingles in adults aged ...
Posted by Michael Wonder on 04 Sep 2021
COVID-19 vaccine: Spikevax (elasomeran)
4 September 2021 - On 3 September 2021, the TGA granted provisional approval to Moderna Australia for the use of ...
Posted by Michael Wonder on 04 Sep 2021
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...
Posted by Michael Wonder on 04 Sep 2021
Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
3 September 2021 - As Democrats design a way to use the government’s leverage to lower drug prices for seniors, ...
Posted by Michael Wonder on 03 Sep 2021
Impel NeuroPharma announces U.S. FDA approval of Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine
3 September 2021 - Commercial launch of Trudhesa is planned for early October 2021. ...
Posted by Michael Wonder on 03 Sep 2021
Acute myeloid leukaemia drug Xospata nears getting insurance benefits
3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...
Posted by Michael Wonder on 03 Sep 2021
Heart failure med Jardiance scores MHRA approval
2 September 2021 - Eli Lilly and Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) has scored approval from the UK MHRA ...
Posted by Michael Wonder on 03 Sep 2021
Ultomiris approved in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria
3 September 2021 - Approval based on interim results from Phase 3 trial demonstrating complete terminal complement inhibition with reduced ...
Posted by Michael Wonder on 03 Sep 2021
FDA acceptance for filing of new drug application for trientine tetrahydrochloride for the treatment of Wilson’s disease
2 September 2021 - New drug application supported by positive data from Phase 3 CHELATE clinical trial. ...
Posted by Michael Wonder on 02 Sep 2021
Novartis gets FDA fast track designation for LNA043 in knee osteoarthritis
2 September 2021 - Novartis AG on Thursday said the U.S. FDA granted fast track designation to LNA043 for the ...
Posted by Michael Wonder on 02 Sep 2021
Patients in the Netherlands wait 1.5 years for access to new medicines
2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...
Posted by Michael Wonder on 02 Sep 2021
A collaborative pilot on current awareness alerts for disinvestment and horizon scanning
31 August 2021 - In 2019, members of the Health Technology Assessment international Interest Group for Disinvestment and Early Awareness and ...
Posted by Michael Wonder on 02 Sep 2021
House Committees demand FDA records on Alzheimer’s drug approval
2 September 2021 - The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter. ...
Posted by Michael Wonder on 02 Sep 2021
FDA reaches milestone in competitive generic therapy drug approvals
2 September 2021 - This week, the FDA reached the milestone of approving more than 100 generic drug applications with a ...
Posted by Michael Wonder on 02 Sep 2021
Pfizer’s acromegaly treatment receives reimbursement
2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...